Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
/ 491 items
#XY Event-Driven Stocks↓
Werewolf and Ambros Merge in $150M Deal to Advance First Potential FDA-Approved Treatment for CRPS-1
Werewolf and Ambros merge in all-stock deal with oversubscribed $150M funding to advance neridronate as potential first FDA-approved CRPS-1 treatment.
What Makes Nuvation Bio a “Low-Risk, High-Reward” Stock According to Cantor
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.
Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Phase 2 RENEW trial underway; interim data expected in H2 2026.
Ultragenyx’s GENGLYCOS Becomes First FDA-Approved Gene Therapy for Glycogen Storage Disease Type Ia
Ultragenyx’s GENGLYCOS receives accelerated FDA approval as the first gene therapy targeting the root cause of GSDIa in patients aged 8 and older.